List view / Grid view
28 May 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Incyte Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen...
28 May 2014 | By Pfizer
The nation’s most prescribed acid blocker brand is now available without a prescription at retailers nationwide...
28 May 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party...
28 May 2014 | By Amgen
New data reinforces commitment to personalized medicine and highlights advances in immunotherapy platform...
27 May 2014 | By Daiichi Sankyo
Dainippon Sumitomo Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd. announced that they have entered into a license agreement for the commercialization of lurasidone hydrochloride...
27 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched the antiplatelet agent Efient® 3.75mg/5mg Tablets in Japan...
23 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has received approval in Japan for partial modification to RANMARKⓇ...
23 May 2014 | By Roche
Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukemia...
23 May 2014 | By Novartis
Novartis announced that the Committee for Medicinal Products for Human Use has adopted a negative opinion for the use of RLX030 in the treatment of acute heart failure...
23 May 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for umeclidinium...
23 May 2014 | By Boehringer Ingelheim
The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company...
22 May 2014 | By Novartis
Novartis will showcase the results of research efforts to target disease pathways with more than 150 abstracts at two upcoming cancer-focused meetings...
22 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces the next step in the clinical development of idarucizumab, the investigational antidote for rapid reversal of dabigatran-induced anticoagulation...
22 May 2014 | By Daiichi Sankyo
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases...
21 May 2014 | By Lucideon
Lucideon is pleased to announce it has invested in the latest Agilent 7900 Quadrapole Inductively Coupled Plasma – Mass Spectrometry (ICP-MS)...
